Smithkline Beecham Corporation

The Johns Hopkins University

Glaxosmithkline LLC

Other

Glaxo Group Limited

Connie L Erickson-Miller

Kristine Kay Kikly

Julian Jenkins

Juan I Luengo

Kevin J Duffy

Bruce Scott Bochner

Robert Schleimer

Sophie Visonneau

Julie A Abrahamson

Stephen Dudley Holmes

T Esra Nutku

Peter R Young

James David Winkler

Antony N Shaw

Kenneth Wiggall

Alexander H Taylor

Alan T Price

Michael Arning

Anna Kalota

Alan Gewirtz

Daniel F Eppley

Nannan Liu

Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human.

Non-peptide thrombopoietin receptor agonist in the treatment of cancer and pre-cancerous syndromes

The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.

Methods of administration of thrombopoietin agonist compounds

The present invention provides methods of inhibiting human myeloid leukemia cell growth and proliferation by administering a thrombopoietin receptor agonist (TpoRA), a derivative, or variant thereof, to an individual with AML.

Thrombopoietin receptor agonist (TpoRA) kills acute human myeloid leukemia cells

Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.

Method of treating thrombocytopenia

Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents.

Sialoadhesin factor-2 antibodies

Methods of use of sialoadhesin factor-2 antibodies

Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Thrombopoietin mimetics

SAF-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SAF-2 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Sialoadhesin family member-2 (SAF-2)

Growing community of inventors

King of Prussia, PA, United States of America

Connie L Erickson-Miller